Investigation of Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneous Deuterated DMT (CYB004) in Depression and Anxiety Disorders

The primary objective of this study is to evaluate the **safety**, **pharmacodynamics**, and **pharmacokinetics** of increasing doses of subcutaneously administered deuterated DMT (CYB004) in healthy subjects. This investigation is clinically relevant as it aims to determine the tolerability and metabolic profile of CYB004, which could have implications for its potential therapeutic use in treating **depression and anxiety disorders**. Understanding the safety and pharmacokinetic properties is crucial for assessing the feasibility of further clinical development.

The clinical trial focuses on **depression and anxiety disorders** and involves a study population that includes only female participants. The age range of the participants is categorized as adults, specifically those aged 18 to 64 years. The trial population is selected from a vulnerable group, although specific selection criteria are not provided. The sponsor has not disclosed the total number of participants involved in the study. Information regarding lifestyle considerations such as diet, physical activity, or habits is not available. The sponsor has not provided detailed inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **safety**, pharmacodynamics, and pharmacokinetics of increasing doses of subcutaneously administered deuterated DMT (CYB004) in healthy subjects. This study is a Phase 3 trial, which is randomized, double-blind, and controlled, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is expected to commence recruitment on December 4, 2023, and is estimated to conclude by October 31, 2024.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion. Following successful screening, participants will be randomized into different dosing groups. Throughout the trial, there will be multiple follow-up visits to monitor the participants' response to the treatment, assess any adverse effects, and collect pharmacokinetic data. These visits are crucial for ensuring participant safety and the integrity of the data collected.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment. The expected length of participant involvement will vary depending on the dosing schedule and response to the treatment, but it is anticipated to last several months. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study protocols, or withdraw consent. The trial aims to provide valuable insights into the treatment of **depression and anxiety disorders**, contributing to the development of new therapeutic options.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatment protocols accurately.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on December 4, 2023, with an estimated completion date of October 31, 2024. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The study will adhere to rigorous standards typical of Phase 3 trials, ensuring that the data collected is robust and reliable for evaluating the treatment's effectiveness. The trial's design and execution will be aligned with regulatory requirements and scientific best practices to ensure the validity of the efficacy outcomes.